Get started
Author

Surendra Petlu

Observed names: S Petlu, S. Petlu
Observed institution: Suven Life Sciences (India)
ORCID: 0009-0009-4486-0786
Observed ORCID: 0009-0009-4486-0786
OpenAlex ID: A5080357403
Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer’s Disease
2021 · Ramakrishna Nirogi, Abdul Rasheed Mohammed, et al. · Journal of Medicinal Chemistry · 18
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation
2021 · Ramakrishna Nirogi, Vijay Benade, et al. · Psychopharmacology · 16
Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders
2021 · Ramakrishna Nirogi, Venkata R Grandhi, et al. · Journal of Psychopharmacology · 9
Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization
2022 · Ramakrishna Nirogi, Renny Abraham, et al. · Psychopharmacology · 8
Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling
2023 · Ramakrishna Nirogi, Venkata Ramalingayya Grandhi, et al. · European Journal of Pharmacology · 7
0054 SUVN-G3031, a Histamine H3 Receptor Inverse Agonist Produces Wake Promoting Effect in Orexin-2-saporin Lesioned Rats
2019 · Vijay Benade, Saivishal Daripelli, et al. · SLEEP · 3
Update on the Development of SUVN‐I6107: A True Positive Allosteric Modulator of the Muscarinic M1 Acetylcholine Receptor for the Treatment of Dementia
2025 · Vijay Benade, Anil Shinde, et al. · Alzheimer s & Dementia · 1
0051 Samelisant, a H3 Receptor Inverse Agonist for the Potential Treatment of Excessive Daytime Sleepiness in Parkinson’s Disease
2023 · Ramakrishna Nirogi, Vijay Benade, et al. · SLEEP · 1
PDF
In Vitro Reaction Phenotyping and Projection of Drug Interactions Mediated by Cytochrome P450 Enzymes for Central Nervous System Drugs as Victims: Implications for Safety in Vulnerable Populations
2026 · Veera Raghava Chowdary Palacharla, Ramakrishna Nirogi, et al. · Drug Metabolism and Disposition
1285 Rationale and Study Design of Samelisant (SUVN-G3031) for the Treatment of Cataplexy in Type 1 Narcolepsy Patients
2025 · Ramakrishna Nirogi, Vinod Kumar Goyal, et al. · SLEEP
PDF
Efficacy of a Muscarinic (M1) Positive Allosteric Modulator, SUVN‐I7016031 in Animal Models of Dementia
2024 · Renny Abraham, Rajesh Babu Medapati, et al. · Alzheimer s & Dementia
PDF
5‐HT1A Receptor Agonist, SUVN‐N9503012 for the Treatment of Dementia and Associated Neuropsychiatric Disorders
2023 · Renny Abraham, Surendra Petlu, et al. · Alzheimer s & Dementia
PDF
Samelisant (SUVN-G3031), a Histamine H3 Receptor Inverse Agonist in Animal Models of Sleep Disorders
2022 · V. Benade, R. Abraham, et al. · Sleep Medicine
0265 Samelisant (SUVN-G3031), a Histamine H3 Receptor Inverse Agonist in Animal Models of Narcolepsy
2022 · Vijay Benade, Renny Abraham, et al. · SLEEP
PDF
0008 SUVN-G3031, A Histamine H3 Receptor Inverse Agonist Produces Robust Wake Promoting and Anticataplectic Activity in Orexin Knockout Mice
2020 · V Benade, S Daripelli, et al. · SLEEP
SUVN-G3031, A histamine H3 receptor inverse agonist produces wake promoting and anti-cataplectic effects in hypocretin-2-saporin lesioned rats
2019 · S. Daripelli, V. Benade, et al. · Sleep Medicine
P3‐193: Suvn‐502: In‐vitro Pharmacological Profile of a Pure 5‐ht6 Receptor Antagonist
2019 · Ramkumar Subramanian, Venkat Reddy Mekala, et al. · Alzheimer s & Dementia
PDF
P1‐077: In‐vitro Characterization of Suvn‐i2004: a Novel Muscarinic M1 Positive Allosteric Modulator
2018 · Ramkumar Subramanian, Venkat Reddy Mekala, et al. · Alzheimer s & Dementia
P3‐455: Suvn‐m8036, a Serotonergic and Dopaminergic Modulator, Alleviates Psychosis and Depression
2018 · Arun Babu Vuyyuru, Rajesh Kallepalli, et al. · Alzheimer s & Dementia
P3‐273: Neurochemical and Electrophysiological Characterization of Suvn‐i6107, a Novel Muscarinic M1 Receptor Positive Allosteric Modulator
2018 · Gopinadh Bhyrapuneni, Saivishal Daripelli, et al. · Alzheimer s & Dementia
Works count: 20
Citation count: 63
H-index: 5
I10-index: 2
Year
Topic
Type